Toxicity Induced by Madopar (l-DOPA) during Curing Parkinson’s Disease by Inhibiting Mitochondrial Function and AKT Pathway

Ting-Mei Wang; Yi-Fang Li; Hiroshi Kurihara; Rong-Rong He

Toxicity Induced by Madopar (l-DOPA) during Curing Parkinson’s Disease by Inhibiting Mitochondrial Function and AKT Pathway

Ting-Mei Wang, Yi-Fang Li, Hiroshi Kurihara, Rong-Rong He

Abstract

Madopar is an effective drug being used clinically for curing Parkinson’s disease (PD) nowadays. However, a growing number of studies found that the Madopar has a falling trend in curative effect including dyskinesia and the reasons are still unknown very well. In order to invest the reasons, we constructed 6-OHDA-induced rat PD model including control group, 6-OHDA group and Madopar + 6-OHDA group, respectively. We detected the behaviour of rotation and roll-rod behaviours 2 weeks later, and the results showed no protection effect and appeared SD rats’ abnormal behaviours. l-dopa treated SH-SY5Y cells for 48 h, cell viability has been inhibited and level of ROS in mitochondria has increased. By detecting levels of apoptosis-related proteins, p-AKT/AKT and Bax/Bcl2 found l-dopa-induced cell apoptosis and death. The decreasing of Sirt3 in mitochondria with the treat of l-DOPA suggests a relationship with mitochondrial function. In a word, the inhibition function of mitochondria and apoptosis in DA neuron cell was the main reasons of l-dopa, which played a weak role in anti-PD.

Keywords

Madopar, l-dopa, ROS, p-AKT, AKT, Bax, Bcl2, Parkinson’s disease, PD

Full Text:

References

Dagur G, Warren K, Schwamb R, Dalpiaz A, Gandhi J, Khan S. Neuro-urological manifestations of Parkinson’s disease. Int J Neurosci. 2016;126:481–487.

Lindholm D, Mäkelä J, Di Liberto V, Mudo G, Belluardo N, Eriksson O, et al. Current disease modifying approaches to treat Parkinson’s disease. Cell Mol Life Sci. 2016;73:1365–79.

Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–144.

Ishida Y, Ebihara K, Tabuchi M, Imamura S, Sekiguchi K, Mizoguchi K, et al. Yokukansan, a traditional Japanese medicine, enhances the l-DOPA-induced rotational response in 6-hydroxydopamine-lesioned rats: possible inhibition of COMT. Biol Pharm Bull. 2016;39:104–113.

Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, et al. Modulation of serotonergic transmission by eltoprazine in l-DOPA-induced dyskinesia: behavioral, molecular, and synaptic mechanisms. Neurobiol Dis. 2016;86:140–153.

Park KH, Shin KS, Zhao TT, Park HJ, Lee KE, Lee MK. l-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells. Neuropharmacology. 2016;101:87–97.

Nikolaus S, Beu M, de Souza Silva MA, Huston JP, Hautzel H, Mattern C, et al. Relationship between l-DOPA-induced reduction in motor and exploratory activity and striatal dopamine D-2 receptor binding in the rat. Front Behav Neurosci. 2016;10:36.

Jang W, Park HH, Lee KY, Lee YJ, Kim HT, Koh SH. 1,25-dyhydroxyvitamin D-3 attenuates l-DOPA-induced neurotoxicity in neural stem cells. Mol Neurobiol. 2015;51:558–570.

Lanzillotta A, Porrini V, Bellucci A, Benarese M, Branca C, Parrella E, et al. NF-kappa B in innate neuroprotection and age-related neurodegenerative diseases. Front Neurol. 2015;6:98.

Gangarossa G, Guzman M, Prado VF, Prado MAM, Daumas S, El Mestikawy S, et al. Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia. Neurobiol Dis. 2016;87:69–79.

Park HY, Ryu YK, Kim YH, Park TS, Go J, Hwang JH, et al. Gadd45? ameliorates l-DOPA-induced dyskinesia in a Parkinson’s disease mouse model. Neurobiol Dis. 2016;89:169–79.

Mu X, Yuan X, Du LD, He GR, Du GH. Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats. J Asian Nat Prod Res. 2016;18:65–71.

Zhang X, Li Y, Liu C, Fan R, Wang P, Zheng L, et al. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson’s disease rats. Transl Res. 2015;166:152–162.

Yu ZH, Cai M, Xiang J, Zhang ZN, Zhang JS, Song XL, et al. PI3K/Akt pathway contributes to neuroprotective effect of Tongxinluo against focal cerebral ischemia and reperfusion injury in rats. J Ethnopharmacol. 2016;181:8–19.

Feng X, Wu C, Yang M, Liu Q, Li H, Liu J, et al. Role of PI3K/Akt signal pathway on proliferation of mesangial cell induced by HMGB1. Tissue Cell. 2016;48:121–5.

Bove J, Martinez-Vicente M, Dehay B, Perier C, Recasens A, Bombrun A, et al. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy. 2014;10:889–900.

Rekha KR, Selvakumar GP. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/ probenecid induced C57BL/6 mice model of Parkinson’s disease. Chem Biol Interact. 2014;217:57–66.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences